Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:34:07.876Z.
Calculation as of: 2026-10-06T16:34:07.876Z.
Quote observation: 2026-10-06T16:30:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ee26685a5d6dda55be8f646f5bdd6a865e7c0271b97e419ee039990db4d6ed05
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$1.20M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.10M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.03M
Price/FCF Ratio
N/A
TTM Avg
60791.74
3Y Avg
60791.74
5Y Avg
60791.74
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Propanc Biopharma, Inc. (PPCB) | $1.18M | N/A | N/A | N/A | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.20M | N/A | N/A | N/A | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.15M | N/A | 3.00 | 2.75 | 2.75 |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.10M | N/A | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.06M | N/A | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.03M | N/A | 60791.74 | 60791.74 | 60791.74 |
| NewcelX Ltd. (NCEL)vs › | $1.33M | N/A | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.34M | N/A | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.38M | N/A | N/A | N/A | N/A |
| INVO Fertility, Inc. (IVF)vs › | $1.43M | N/A | 8.14 | 8.14 | 8.14 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
